東湖高新(600133.SH)與子公司共同簽署投資基金合夥企業合夥協議
格隆匯11月8日丨東湖高新(600133.SH)公佈,2019年11月7日,公司、東湖投資、中鉑投資與中鉑濟豐簽署了《武漢東湖高新中鉑大健康股權投資合夥企業(有限合夥)合夥協議》。
本次設立基金總規模1億元,基金設立時首次出資總額為6000萬元人民幣(其中:東湖投資認繳出資100萬元,出資佔比1%;中鉑投資認繳出資10萬元,出資佔比0.1%;東湖高新認繳出資2900萬元,出資佔比29%;中鉑濟豐認繳出資2990萬元,出資佔比29.9%),其餘資金由基金管理人在開放期(本合夥企業成立一年內)負責募集,若開放期結束剩餘資金募集不成功或部分募集,認繳出資總額以實際募集資金為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.